Xilong science stock bar provides Xilong science (002584) stock market trend, five file handicap, pen by pen transaction and other real-time market data, as well as related news information, company announcements, research reports and industry research reports.
1. Xilong Science Co., Ltd (XLSC, stock code: 002584), formerly known as Xilong Chemical Co., Ltd, founded in 1983, was listed on the Shenzhen Stock Exchange in June 2011, and is the first listed chemical reagent company in China.
2. The company is mainly engaged in the research and development, production and sales of chemical reagents (including general-purpose chemical reagents, chemical reagents for PCB, ultra-clean and high-purity chemical reagents), diagnostic reagents, APIs and food additives, and gene sequencing services. It has developed into a professional manufacturer and integrated supplier with strong R&D capability, wide sales coverage and leading comprehensive supporting scale of chemical reagents in China.
3. In 2017, the company and its subsidiary Sichuan Xilong Science passed the review of national high-tech enterprises, the company's application for the qualification of provincial enterprise technology center in Guangdong Province passed successfully, and Foshan Xilong Chemical Co., Ltd. was recognized by the Foshan City Science and Technology Bureau as the Foshan City enterprise high-purity chemical reagent engineering technology center.
4. In 2017, the company and its subsidiaries carried out strategic cooperation with international chemical giants such as BASF (China) Co., Ltd. and AkzoNobel Chemicals (Ningbo) Co., Ltd. to ***share resources and channels, and to carry out comprehensive cooperation through online platforms and offline sales teams, and ***simultaneously enhance the market share and brand influence of products.
5. September 26, 2018 announcement, the company intends to use its own funds of RMB 450 million yuan and Merrill Lynch Huaan *** with the initiation of the establishment of a large health care industry investment and mergers and acquisitions private equity fund (tentative name), industry mergers and acquisitions fund with a total size of RMB 1.8 billion yuan. The main investment direction of the fund is in industry-related fields with favorable industry prospects, such as big health and medical services.
6. The current chairman of the board of directors of the company is Mr. Huang Weipeng, born in January 1961, Chinese nationality, no permanent residency in foreign countries, graduated from the Department of Economics and Management of the Military Economics College of the People's Liberation Army, Sun Yat-sen University, EMBA, and vice chairman of the China Chemical Reagent Industry Association.